Last quarter (Q3 2023), Pacific Biosciences's total revenue was $55.69M, an increase of 72.36% from the same quarter last year. In Q3, Pacific Biosciences's net income was $-65.39M. See Pacific Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 73.34M	$ 128.30M	$ 130.51M	$ 78.89M	$ 90.89M	$ 78.63M
Cost of Revenue	$ 17.16M	$ 79.27M	$ -56.36M	$ 46.33M	$ 56.31M	$ 53.53M
Gross Profit	$ 66.54M	$ 49.03M	$ 58.86M	$ 32.57M	$ 34.58M	$ 25.10M
Operating Expense	$ 173.94M	$ 356.23M	$ -269.30M	$ 136.95M	$ 135.12M	$ 126.08M
Operating Income	$ -297.16M	$ -307.20M	$ -308.68M	$ -104.39M	$ -100.55M	$ -100.99M
Net Non Operating Interest Income Expense	$ -14.42M	$ -14.69M	$ -12.53M	$ -267.00K	$ -2.61M	$ -2.42M
Other Income Expense	$ 32.50M	$ -4.53M	$ -46.33M	$ 134.06M	$ 19.02M	$ 848.00K
Pretax Income	$ -335.38M	$ -314.25M	$ -274.87M	$ 29.40M	$ -84.13M	$ -102.56M
Tax Provision	$ -26.27M	-	$ -93.65M	$ 0.00	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -307.62M	$ -314.25M	$ -181.22M	$ 29.40M	$ -84.13M	$ -102.56M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 191.10M	$ 435.50M	$ -325.65M	$ 183.28M	$ 191.44M	$ 179.61M
Net Income From Continuing And Discontinued Operation	$ -309.10M	$ -314.25M	$ -181.22M	$ 29.40M	$ -84.13M	$ -102.56M
Normalized Income	$ -132.77M	$ -245.15M	-	$ -102.60M	$ -102.13M	$ -102.56M
Interest Expense	-	-	-	$ 267.00K	$ 2.61M	$ 2.42M
EBIT	$ -320.95M	$ -299.56M	$ -262.34M	$ 29.67M	$ -81.52M	$ -100.14M
EBITDA	$ -305.94M	$ -281.60M	$ -250.22M	$ 38.97M	$ -71.58M	$ -92.92M

Currency in USD

Pacific Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing